Takeda to build new plant in Japan

Published: 17-Sep-2010
Manufacturing Finance

For production of oral, solid dosage formulations


Japanese drugmaker Takeda Pharmaceutical Company is to build a new JPY14bn (US$163m; €125m; £104m) manufacturing facility at its plant in Hikari City, Yamaguchi Prefecture in Japan.

Construction of the 13,000m2 facility will begin on 5 October, with completion expected by April 2012.

The company says the new flagship plant will operate 24/7 and conduct high-volume manufacturing of a wide range of oral, solid dosage formulations to treat diabetes and cardiovascular diseases.

  • Companies:
  • Takeda
See more

You may also like

Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

Read more
The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
  2. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  3. £20m Scottish oligonucleotide manufacturing innovation centre now under construction The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's biopharmaceutical presence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Manufacturing

Future thoughts about pharmaceutical manufacturing

COPA-DATA's Giuseppe Menin and his colleagues from an ISPE working group discuss shifting from a systems to a service-oriented architecture
Manufacturing

Takeda opens cell therapy manufacturing facility in Boston

The next-generation cell therapies will initially focuse on oncology with potential to expand into other therapeutic areas
Subscribe now